Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H16O4 |
Molecular Weight | 188.2209 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CCCCCCCC(O)=O
InChI
InChIKey=BDJRBEYXGGNYIS-UHFFFAOYSA-N
InChI=1S/C9H16O4/c10-8(11)6-4-2-1-3-5-7-9(12)13/h1-7H2,(H,10,11)(H,12,13)
Molecular Formula | C9H16O4 |
Molecular Weight | 188.2209 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/?term=2114832
https://www.ncbi.nlm.nih.gov/pubmed/18803456
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/?term=2114832
https://www.ncbi.nlm.nih.gov/pubmed/18803456
Azelaic acid, a naturally occurring saturated dicarboxylic acid found in wheat, rye, and barley, possesses antimicrobial activity, affects keratin production, and reduces inflammation. One of the brand name for azelaic acid is FINACEA,Gel, 15% is indicated for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. Although some reduction of erythema, which was present in patients with papules, and pustules of rosacea occurred in clinical studies, efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated. Rosacea is a common skin condition thought to be primarily an inflammatory disorder. Neutrophils, in particular, have been implicated in the inflammation associated with rosacea and mediate many of their effects through the release of reactive oxygen species. Many effective agents for rosacea, including topical azelaic acid have anti-inflammatory properties. Azelaic acid per se has multiple modes of action in rosacea, but an anti-inflammatory effect achieved by reducing reactive oxygen species appears to be the main pharmacological action. A possible mechanism of action for azelaic acid in the human epidermis includes its possibility to inhibit tyrosinase and of membrane-associated thioredoxin reductase enzymes, this enzyme is shown to regulate tyrosinase through a feedback mechanism involving electron transfer to intracellular thioredoxin, followed by a specific interaction between reduced thioredoxin and tyrosinase.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2505463
Curator's Comment: Azelaic acid is capable of crossing the blood-brain barrier: its concentration in the cerebrospinal fluid is normally in the range of 2-5% of the values in the serum.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P14679 Gene ID: 7299.0 Gene Symbol: TYR Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/2114832 |
2.73 mM [Ki] | ||
Target ID: CHEMBL2096978 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2114832 |
125.0 mM [Ki] | ||
Target ID: GO:1903409 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20967185 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | FINACEA Approved UseFINACEA® (azelaic acid) Gel, 15% is indicated for topical treatment of the inflammatory papules and pustules of mild to
moderate rosacea. Although some reduction of erythema which was present in patients with papules and pustules of
rosacea occurred in clinical studies, efficacy for treatment of erythema in rosacea in the absence of papules and pustules
has not been evaluated. Launch Date1.04068802E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
112 ng/mL |
1 g single, topical dose: 1 g route of administration: Topical experiment type: SINGLE co-administered: |
AZELAIC ACID unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
136 ng/mL |
1 g 2 times / day steady-state, topical dose: 1 g route of administration: Topical experiment type: STEADY-STATE co-administered: |
AZELAIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
613 ng × h/mL |
1 g single, topical dose: 1 g route of administration: Topical experiment type: SINGLE co-administered: |
AZELAIC ACID unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
686 ng × h/mL |
1 g 2 times / day steady-state, topical dose: 1 g route of administration: Topical experiment type: STEADY-STATE co-administered: |
AZELAIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12 h |
1 g single, topical dose: 1 g route of administration: Topical experiment type: SINGLE co-administered: |
AZELAIC ACID unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
A comparative study of 20% azelaic acid cream monotherapy versus a sequential therapy in the treatment of melasma in dark-skinned patients. | 2002 |
|
The management of rosacea. | 2002 |
|
Assessment of topical hypopigmenting agents on solar lentigines of Asian women. | 2002 |
|
Bioactive constituents of the seeds of Brucea javanica. | 2002 Aug |
|
Sensitive and accurate quantitation of monoepoxy fatty acids in thermoxidized oils by gas-liquid chromatography. | 2002 Dec 20 |
|
Structure of a novel diterpenoid ester, fritillahupehin from bulbs of Fritillaria hupehensis Hsiao and K.C. Hsia. | 2002 Jul |
|
Total synthesis of (-)-minquartynoic acid: an anti-cancer, anti-HIV natural product. | 2002 Jul 25 |
|
[Studies on chemical constituents of root of Cichorium intybus]. | 2002 Mar |
|
Azelaic acid (20%) cream in the treatment of acne vulgaris. | 2002 Mar |
|
Cocrystal structures of diaminopimelate decarboxylase: mechanism, evolution, and inhibition of an antibiotic resistance accessory factor. | 2002 Nov |
|
Unknown peaks in GC-MS analyses of Guthrie cards blood samples might be the result of sample contamination by the black markings of the card. | 2002 Oct |
|
Fluid shear stress attenuates hydrogen peroxide-induced c-Jun NH2-terminal kinase activation via a glutathione reductase-mediated mechanism. | 2002 Oct 18 |
|
Topical treatment in acne: current status and future aspects. | 2003 |
|
Separation of homologues and isomers of linear alkylbenzenesulfonates by capillary electrophoresis with sodium dodecyl sulfate, carboxylic acids and bile salts. | 2003 Feb |
|
Urotropin azelate: a rather unwilling co-crystal. | 2003 Feb |
|
Management of acne. | 2003 Jan |
|
Atmospheric pressure mass spectrometry: a new analytical chemical characterization method for dissolved organic matter in rainwater. | 2003 Jan 1 |
|
Gas chromatography-mass spectrometry profile of urinary organic acids of Wistar rats orally treated with ozonized unsaturated triglycerides and ozonized sunflower oil. | 2003 Jan 15 |
|
Investigation of surface changes of nanoparticles using TM-AFM phase imaging. | 2003 Jun 15 |
|
Analgesic effects of intra-nasal enkephalins. | 2003 Sep |
|
Azelaic acid (Finacea) for rosacea. | 2003 Sep 15 |
|
Acne and its management beyond the age of 35 years. | 2004 |
|
Photoelectron resonance capture ionization mass spectrometry: a soft ionization source for mass spectrometry of particle-phase organic compounds. | 2004 |
|
Optimal management of recalcitrant disorders of hyperpigmentation in dark-skinned patients. | 2004 |
|
Azelaic acid : a viewpoint by Aditya K. Gupta. | 2004 |
|
Azelaic acid: a viewpoint by Susan Bershad. | 2004 |
|
Azelaic acid 15% gel: in the treatment of papulopustular rosacea. | 2004 |
|
Interventions for rosacea. | 2004 |
|
New rosacea drug gets the red out. | 2004 Jan |
|
The role of topical metronidazole in the treatment of rosacea. | 2004 Jan |
|
Phototoxic effects of topical azelaic acid, benzoyl peroxide and adapalene were not detected when applied immediately before UVB to normal skin. | 2004 Jul-Aug |
|
Conformationally constrained dipeptide surrogates with aromatic side-chains: synthesis of 4-aryl indolizidin-9-one amino acids by conjugate addition to a common alpha,omega-diaminoazelate enone intermediate. | 2004 Mar 5 |
|
Differential conductance switching of planar tunnel junctions mediated by oxidation/reduction of functionally protected ferrocene. | 2004 May 26 |
|
[Azelaic acid 15% gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies]. | 2004 Oct |
|
Hyperpigmentation: an overview of the common afflictions. | 2004 Oct |
|
Enhancement of the release of azelaic acid through the synthetic membranes by inclusion complex formation with hydroxypropyl-beta-cyclodextrin. | 2005 Apr 11 |
|
Interventions for rosacea. | 2005 Jul 20 |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
The rigor of trials evaluating Rosacea treatments. | 2005 Mar |
|
Present and future rosacea therapy. | 2005 Mar |
|
Rosacea and its management: an overview. | 2005 May |
|
Cumulative irritation potential of metronidazole gel compared to azelaic acid gel after repeated applications to healthy skin. | 2005 Nov-Dec |
|
[Rosacea. Clinical features, pathogenesis and therapy]. | 2005 Sep |
|
The face and mind evaluation study: an examination of the efficacy of rosacea treatment using physician ratings and patients' self-reported quality of life. | 2005 Sep-Oct |
|
The use of topical azelaic acid for common skin disorders other than inflammatory rosacea. | 2006 Feb |
|
Case studies. | 2006 Feb |
|
A clinical overview of azelaic acid. | 2006 Feb |
|
The rationale for advancing the formulation of azelaic acid vehicles. | 2006 Feb |
|
The evolution of azelaic acid. | 2006 Feb |
|
Treatment of melasma. | 2006 May |
Patents
Sample Use Guides
Apply and gently massage into the affected areas on the face twice daily (morning and evening). Patients should be reassessed if no improvement is observed upon completing 12 weeks of therapy.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7640879
Using a clonogenic assay in vitro, it has been shown that exposure to azelaic acid (1-100 mM) for 24 hours has a dose-dependent effect on the survival of the colony-forming ability of murine (B16) and human (HMB2, and SK23) melanoma cells as compared with a non-melanotic non-tumoral Chinese hamster cell line (CHO). Both human cell lines were more sensitive to the diacid than the murine cells, and the HMB2 cells were more sensitive than the SK23 cells.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:26:07 UTC 2023
by
admin
on
Fri Dec 15 15:26:07 UTC 2023
|
Record UNII |
F2VW3D43YT
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000008841
Created by
admin on Fri Dec 15 15:26:07 UTC 2023 , Edited by admin on Fri Dec 15 15:26:07 UTC 2023
|
||
|
NDF-RT |
N0000008841
Created by
admin on Fri Dec 15 15:26:07 UTC 2023 , Edited by admin on Fri Dec 15 15:26:07 UTC 2023
|
||
|
NDF-RT |
N0000009982
Created by
admin on Fri Dec 15 15:26:07 UTC 2023 , Edited by admin on Fri Dec 15 15:26:07 UTC 2023
|
||
|
NCI_THESAURUS |
C28394
Created by
admin on Fri Dec 15 15:26:07 UTC 2023 , Edited by admin on Fri Dec 15 15:26:07 UTC 2023
|
||
|
LOINC |
79495-8
Created by
admin on Fri Dec 15 15:26:07 UTC 2023 , Edited by admin on Fri Dec 15 15:26:07 UTC 2023
|
||
|
WHO-ATC |
D10AX03
Created by
admin on Fri Dec 15 15:26:07 UTC 2023 , Edited by admin on Fri Dec 15 15:26:07 UTC 2023
|
||
|
WHO-VATC |
QD10AX03
Created by
admin on Fri Dec 15 15:26:07 UTC 2023 , Edited by admin on Fri Dec 15 15:26:07 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB05648MIG
Created by
admin on Fri Dec 15 15:26:07 UTC 2023 , Edited by admin on Fri Dec 15 15:26:07 UTC 2023
|
PRIMARY | |||
|
19493
Created by
admin on Fri Dec 15 15:26:07 UTC 2023 , Edited by admin on Fri Dec 15 15:26:07 UTC 2023
|
PRIMARY | |||
|
123-99-9
Created by
admin on Fri Dec 15 15:26:07 UTC 2023 , Edited by admin on Fri Dec 15 15:26:07 UTC 2023
|
PRIMARY | |||
|
618278
Created by
admin on Fri Dec 15 15:26:07 UTC 2023 , Edited by admin on Fri Dec 15 15:26:07 UTC 2023
|
ALTERNATIVE | |||
|
DB00548
Created by
admin on Fri Dec 15 15:26:07 UTC 2023 , Edited by admin on Fri Dec 15 15:26:07 UTC 2023
|
PRIMARY | |||
|
100000091937
Created by
admin on Fri Dec 15 15:26:07 UTC 2023 , Edited by admin on Fri Dec 15 15:26:07 UTC 2023
|
PRIMARY | |||
|
AZELAIC ACID
Created by
admin on Fri Dec 15 15:26:07 UTC 2023 , Edited by admin on Fri Dec 15 15:26:07 UTC 2023
|
PRIMARY | |||
|
C47407
Created by
admin on Fri Dec 15 15:26:07 UTC 2023 , Edited by admin on Fri Dec 15 15:26:07 UTC 2023
|
PRIMARY | |||
|
CHEMBL1238
Created by
admin on Fri Dec 15 15:26:07 UTC 2023 , Edited by admin on Fri Dec 15 15:26:07 UTC 2023
|
PRIMARY | |||
|
F2VW3D43YT
Created by
admin on Fri Dec 15 15:26:07 UTC 2023 , Edited by admin on Fri Dec 15 15:26:07 UTC 2023
|
PRIMARY | |||
|
18602
Created by
admin on Fri Dec 15 15:26:07 UTC 2023 , Edited by admin on Fri Dec 15 15:26:07 UTC 2023
|
PRIMARY | |||
|
270
Created by
admin on Fri Dec 15 15:26:07 UTC 2023 , Edited by admin on Fri Dec 15 15:26:07 UTC 2023
|
PRIMARY | |||
|
DTXSID8021640
Created by
admin on Fri Dec 15 15:26:07 UTC 2023 , Edited by admin on Fri Dec 15 15:26:07 UTC 2023
|
PRIMARY | |||
|
204-669-1
Created by
admin on Fri Dec 15 15:26:07 UTC 2023 , Edited by admin on Fri Dec 15 15:26:07 UTC 2023
|
PRIMARY | |||
|
m2168
Created by
admin on Fri Dec 15 15:26:07 UTC 2023 , Edited by admin on Fri Dec 15 15:26:07 UTC 2023
|
PRIMARY | Merck Index | ||
|
2266
Created by
admin on Fri Dec 15 15:26:07 UTC 2023 , Edited by admin on Fri Dec 15 15:26:07 UTC 2023
|
PRIMARY | |||
|
7659
Created by
admin on Fri Dec 15 15:26:07 UTC 2023 , Edited by admin on Fri Dec 15 15:26:07 UTC 2023
|
PRIMARY | |||
|
F2VW3D43YT
Created by
admin on Fri Dec 15 15:26:07 UTC 2023 , Edited by admin on Fri Dec 15 15:26:07 UTC 2023
|
PRIMARY | |||
|
48131
Created by
admin on Fri Dec 15 15:26:07 UTC 2023 , Edited by admin on Fri Dec 15 15:26:07 UTC 2023
|
PRIMARY | |||
|
HH-64
Created by
admin on Fri Dec 15 15:26:07 UTC 2023 , Edited by admin on Fri Dec 15 15:26:07 UTC 2023
|
PRIMARY | |||
|
7484
Created by
admin on Fri Dec 15 15:26:07 UTC 2023 , Edited by admin on Fri Dec 15 15:26:07 UTC 2023
|
PRIMARY | |||
|
Azelaic Acid
Created by
admin on Fri Dec 15 15:26:07 UTC 2023 , Edited by admin on Fri Dec 15 15:26:07 UTC 2023
|
PRIMARY | |||
|
5883
Created by
admin on Fri Dec 15 15:26:07 UTC 2023 , Edited by admin on Fri Dec 15 15:26:07 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |